-
ContraFect Corporation (NASDAQ: CFRX) shares are trading higher Thursday morning. However, there is no specific news to justify the move.
-
Wednesday morning, ContraFect announced the dosing of the first patient in Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention procedure in patients with chronic prosthetic joint infections of the knee due to Staphylococcus aureus or Coagulase-Negative Staphylococci.
-
The study was initiated earlier this month.
-
ContraFect stock is gaining on heavy volume, with a session volume of 55 million shares traded, compared to the trailing 100-day volume of 3.08 million shares.
-
According to data from Benzinga Pro, CFRX has a 52-week high of $362.4 and a 52-week low of $0.90.
-
Price Action: CFRX shares are up 68.20% at $2.22 on the last check Thursday.
Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article What’s Going On With ContraFecta Stock Today originally appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
